<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:32:48Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6494360" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6494360</identifier>
        <datestamp>2020-05-01</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="pmc">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>American Society of Clinical Oncology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6494360</article-id>
              <article-id pub-id-type="pmcid">PMC6494360</article-id>
              <article-id pub-id-type="pmc-uid">6494360</article-id>
              <article-id pub-id-type="pmid">30817251</article-id>
              <article-id pub-id-type="pmid">30817251</article-id>
              <article-id pub-id-type="publisher-id">1802031</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.18.02031</article-id>
              <article-categories>
                <subj-group subj-group-type="subjects">
                  <compound-subject>
                    <compound-subject-part content-type="code"/>
                    <compound-subject-part content-type="label">[GUC67] Genitourinary: Prostate, advanced stage: Immunotherapy</compound-subject-part>
                  </compound-subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>RAPID COMMUNICATION</subject>
                  <subj-group>
                    <subject>Genitourinary Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer</article-title>
                <alt-title alt-title-type="short">PROSTVAC Â± GM-CSF in Asymptomatic/Minimally Symptomatic mCRPC</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gulley</surname>
                    <given-names>James L.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Borre</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <degrees>PhD, DMSc</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vogelzang</surname>
                    <given-names>Nicholas J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ng</surname>
                    <given-names>Siobhan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Agarwal</surname>
                    <given-names>Neeraj</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parker</surname>
                    <given-names>Chris C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pook</surname>
                    <given-names>David W.</given-names>
                  </name>
                  <degrees>MD, MBBS</degrees>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rathenborg</surname>
                    <given-names>Per</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Flaig</surname>
                    <given-names>Thomas W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carles</surname>
                    <given-names>Joan</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saad</surname>
                    <given-names>Fred</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shore</surname>
                    <given-names>Neal D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff12">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Liddy</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heery</surname>
                    <given-names>Christopher R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff13">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gerritsen</surname>
                    <given-names>Winald R.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff14">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Priou</surname>
                    <given-names>Frank</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff15">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Langkilde</surname>
                    <given-names>Niels C.</given-names>
                  </name>
                  <degrees>DMSc</degrees>
                  <xref ref-type="aff" rid="aff16">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Novikov</surname>
                    <given-names>Andrey</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff17">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kantoff</surname>
                    <given-names>Philip W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff18">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>National Institutes of Health, Bethesda, MD</aff>
                <aff id="aff2"><label><sup>2</sup></label>Aarhus Universitetshospital, Ãarhus, Denmark</aff>
                <aff id="aff3"><label><sup>3</sup></label>Comprehensive Cancer Centers of Nevada, Las Vegas, NV</aff>
                <aff id="aff4"><label><sup>4</sup></label>St John of God Subiaco Hospital, Subiaco, Western Australia, Australia</aff>
                <aff id="aff5"><label><sup>5</sup></label>University of Utah Huntsman Cancer Institute, Salt Lake City, UT</aff>
                <aff id="aff6"><label><sup>6</sup></label>Royal Marsden Hospital, Sutton, United Kingdom</aff>
                <aff id="aff7"><label><sup>7</sup></label>Monash Medical Centre, Bentleigh, Victoria, Australia</aff>
                <aff id="aff8"><label><sup>8</sup></label>Herlev Hospital, Herlev, Denmark</aff>
                <aff id="aff9"><label><sup>9</sup></label>University of Colorado Cancer Center, Aurora, CO</aff>
                <aff id="aff10"><label><sup>10</sup></label>Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain</aff>
                <aff id="aff11"><label><sup>11</sup></label>Centre Hospitalier de l'UniversitÃ© de MontrÃ©al, MontrÃ©al, Quebec, Canada</aff>
                <aff id="aff12"><label><sup>12</sup></label>Carolina Urologic Research Center, Myrtle Beach, SC</aff>
                <aff id="aff13"><label><sup>13</sup></label>Bavarian Nordic, Morrisville, NC</aff>
                <aff id="aff14"><label><sup>14</sup></label>Radboudumc, Nijmegen, the Netherlands; </aff>
                <aff id="aff15"><label><sup>15</sup></label>Centre Hospitalier DÃ©partemental, La Roche sur Yon, France</aff>
                <aff id="aff16"><label><sup>16</sup></label>Aalborg Universitethospital, Aalborg, Denmark</aff>
                <aff id="aff17"><label><sup>17</sup></label>North-Western State Medical University, Saint Petersburg, Russia</aff>
                <aff id="aff18"><label><sup>18</sup></label>Memorial Sloan Kettering Cancer Center, New York, NY</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">James L. Gulley, MD, PhD, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: <email>gulleyj@mail.nih.gov</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>1</day>
                <month>5</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>2</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>5</month>
                <year>2020</year>
              </pub-date>
              <!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
              <volume>37</volume>
              <issue>13</issue>
              <fpage>1051</fpage>
              <lpage>1061</lpage>
              <history>
                <date date-type="accepted">
                  <day>1</day>
                  <month>2</month>
                  <year>2019</year>
                  <!--string-date: accepted on February 1, 2019-->
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© 2019 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2019</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>Licensed under the Creative Commons Attribution 4.0 License: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:title="pdf" xlink:href="JCO.18.02031.pdf"/>
              <abstract>
                <sec>
                  <title>PURPOSE</title>
                  <p>PROSTVAC, a viral vectorâbased immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer in a phase II study. This phase III study further investigated those findings.</p>
                </sec>
                <sec>
                  <title>PATIENTS AND METHODS</title>
                  <p>Patients were randomly assigned to PROSTVAC (Arm V; n = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo (Arm P; n = 433), stratified by prostate-specific antigen (less than 50 ng/mL <italic>v</italic> 50 ng/mL or more) and lactate dehydrogenase (less than 200 <italic>v</italic> 200 U/L or more). Primary end point was OS. Secondary end points were patients alive without events (AWE)ânamely, radiographic progression, pain progression, chemotherapy initiation, or deathâat 6 months and safety. The study design was a superiority trial of PROSTVAC (Arm V or Arm VG) versus Arm P. Three interim analyses were planned.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>At the third interim analysis, criteria for futility were met and the trial was stopped early. Neither active treatment had an effect on median OS (Arm V, 34.4 months; hazard ratio, 1.01; 95% CI, 0.84 to 1.20; <italic>P</italic> = .47; Arm VG, 33.2 months; hazard ratio, 1.02; 95% CI, 0.86 to 1.22; <italic>P</italic> = .59; Arm P, 34.3 months). Likewise, AWE at 6 months was similar (Arm V, 29.4%; odds ratio, 0.96; 95% CI, 0.71 to 1.29; Arm VG, 28.0%; odds ratio, 0.89; 95% CI, 0.66 to 1.20; placebo, 30.3%). Adverse events were similar for the treatment and placebo groups, with the most common being injection site reactions (62% to 72%) and fatigue (21% to 24%). Arrhythmias were the most common cardiac-related events (1.4% to 3.5%). There were no reports of either myocarditis or pericarditis. Serious treatment-related events occurred in less than 1% of all patients.</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>Whereas PROSTVAC was safe and well tolerated, it had no effect on OS or AWE in metastatic castration-resistant prostate cancer. Combination therapy is currently being explored in clinical trials.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="2"/>
                <table-count count="5"/>
                <equation-count count="0"/>
                <ref-count count="34"/>
                <page-count count="12"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name> SJS Export </meta-name>
                  <meta-value>v1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>The treatment algorithm for metastatic castration-resistant prostate cancer (mCRPC) continues to evolve as research brings new survival-prolonging therapies to the clinic. The mainstay of treatment for mCRPC is androgen-deprivation therapy through pharmacologic and surgical strategies.<sup><xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref></sup> During the last decade, second-generation antiandrogen agentsâabiraterone and enzalutamideâhave received US Food and Drug Administration approval for mCRPC.<sup><xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B6" ref-type="bibr">6</xref></sup> Other treatment modalities for mCRPC that have demonstrated overall survival (OS) benefits include chemotherapy (docetaxel and cabazitaxel),<sup><xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B9" ref-type="bibr">9</xref></sup> immunotherapy (sipuleucel-T),<sup><xref rid="B10" ref-type="bibr">10</xref></sup> and targeted Î±-therapy (radium-223).<sup><xref rid="B11" ref-type="bibr">11</xref></sup></p>
              <p>PROSTVAC is an active immunotherapy vaccine that contains prostate-specific antigen (PSA) as the tumor-associated antigen used to generate a T-cell response against prostate cancer. PROSTVAC is composed of a heterologous prime-boost regimen using two different live poxviral-based vectors: PROSTVAC-V, a recombinant vaccinia virus (rilimogene galvacirepvec), and PROSTVAC-F, a recombinant fowlpox virus (rilimogene glafolivec). Both vectors contain transgenes for human PSA and three costimulatory molecules for T cellsâcollectively referred to as TRICOM: B7.1, leukocyte function-associated antigen-3, and intercellular adhesion molecule-1âto enhance immune activation.<sup><xref rid="B12" ref-type="bibr">12</xref></sup> On the basis of the hypothesis of potential enhancement of T-cell responses, PROSTVAC has been evaluated in clinical trials in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF),<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref></sup> a cytokine with immunomodulatory activity<sup><xref rid="B15" ref-type="bibr">15</xref></sup>; however, the necessity of GM-CSF was not established definitively in these earlier studies.</p>
              <p>Results from a randomized, double-blind, phase II trial generated the hypothesis that PROSTVAC might prolong OS, although it did not prolong progression-free survival, the studyâs primary end point, or produce any objective tumor responses.<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref></sup> To validate this hypothesis and confirm the role of GM-CSF as an adjuvant, we designed a phase III trial, the results of which are reported here.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>PATIENTS AND METHODS</title>
              <sec id="s3">
                <title>Patients</title>
                <p>Eligibility criteria included men age 18 years or older with documented asymptomatic or minimally symptomatic evidence of mCRPC and documented progressive disease (either radiologic or by PSA progression), castrate testosterone level less than 50 ng/dL, current use of a gonadotropin-releasing hormone agonist or antagonist (unless surgically castrated), and chemotherapy naÃ¯ve for metastatic prostate cancer (neoadjuvant or adjuvant chemotherapy for primary prostate cancer was permitted if completed more than 3 years before screening). A 6-week washout period was required for patients on antiandrogen therapyâ4 weeks if on flutamide. Concomitant medications to prevent bone loss or skeletal-related events, including bisphosphonates and denosumab, as well as palliative radiotherapy were permitted during the trial.</p>
                <p>Exclusion criteria included cancer-related pain that required scheduled opioid narcoticsâas needed two times per week or fewer was permittedâand current or prior use of sipuleucel-T for prostate cancer.</p>
              </sec>
              <sec id="s4">
                <title>Study Design</title>
                <p>This was a phase III, international, multicenter, randomized, double-blind, placebo-controlled study. Patients were stratified by PSA (less than 50 ng/mL <italic>v</italic> 50 ng/mL or more) and lactate dehydrogenase (less than 200 U/L <italic>v</italic> 200 U/L or more) at screening and block randomly assigned 1:1:1 to PROSTVAC plus GM-CSF (Arm VG), PROSTVAC plus placebo GM-CSF (Arm V), or vaccine placebo plus placebo GM-CSF (Arm P) using an interactive voice response system from a randomization list generated by a third-party vendor. GM-CSF (sargramostim; Leukine [Sanofi, Bridgewater, NJ]; 250 Î¼g, lyophilized), a glycosylated, recombinant human GM-CSF, was manufactured by Genzyme. GM-CSF placebo was USP grade or equivalent bacteriostatic sodium chloride (saline) for injection. GM-CSF was added as adjuvant therapy to one treatment arm to explore whether this immune modulator enhanced the activity of PROSTVAC, as data on its potential benefit in cancer therapy are inconsistent.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B19" ref-type="bibr">19</xref></sup> An empty vector fowlpox was used for the placebo vaccination as it is nonreplicating in humans; has minimal safety risks, including no known effects on cancer progression; and an adverse effect profile, including injection site reactions, that is overlapping and generally indistinguishable from subcutaneously administered vaccinia. This trial is registered with the European Clinical Trial Database (EudraCT 2010-021196-85).</p>
                <p>The study consisted of three periods: screening, treatment, and long-term follow-up (LTFU). During the treatment phase, a total of seven vaccinations were subcutaneously administeredâa single priming immunization of PROSTVAC-V or placebo in week 1 followed by six boosting immunizations with PROSTVAC-F or placebo administered in weeks 3, 5, 9, 13, 17, and 21. Subcutaneous GM-CSF or placebo was administeredâwithin 5 mm of the original injection siteâon the day of immunization and for 3 consecutive days thereafter beginning with week 1, for a total of 28 doses. After the end-of-treatment visitâweek 25/early terminationâall patients were automatically entered into the LTFU phase, with study visits occurring every 6 months. During the treatment phase (approximately 5 months), chemotherapy, immunotherapy (eg, sipuleucel-T) or immunosuppressive therapy (eg, etanercept or natalizumab), systemic corticosteroids (daily or continued use every other day for more than 14 days), anticancer radionuclides, and secondary anticancer hormonal treatments (eg, abiraterone) were prohibited. During LTFU, patients received standard-of-care treatment as determined by the investigator.</p>
                <p>The study was approved by local or central institutional review boards or ethics committees for each participating site and conducted according to the provisions of the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Conference on Harmonization. All patients provided written informed consent before any screening procedures were initiated.</p>
              </sec>
              <sec id="s5">
                <title>Outcomes</title>
                <p>Primary end point of the study was OS, defined as the time between the date of random assignment and the date of death as a result of any cause. Secondary end point was the proportion of patients alive without events (AWE) ânamely, radiographic progression, pain progression, initiation of chemotherapy for prostate cancer, or deathâat 6 months postârandom assignment. Safety end points included adverse events, vital signs, and 12-lead ECG. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Tumor response was according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. Exploratory/other end points included survival on the basis of HLA-A2 status, postvaccination cancer treatments (abiraterone acetate, enzalutamide, or sipuleucel-T), and growth rate constant calculated using PSA values from screening through week 25/end-of-treatment visit.</p>
              </sec>
              <sec id="s6">
                <title>Statistical Analysis</title>
                <p>All efficacy analyses were conducted using the intention-to-treat population, defined as all randomly assigned patients, with analysis according to the randomized treatment arm. Safety analyses were conducted using the full analysis set population, defined as all patients who initiated treatment. Primary analysis was based on a stratified log-rank test. Hazard ratio was estimated using stratified Cox proportional hazards regression analysis, with ties handled by the exact method. Survival data were plotted using the Kaplan-Meier method. An estimated 534 deaths in a between-arm comparison was needed to achieve a target hazard ratio of 0.68 with a one-sided type I error of 0.0125 and a target power of 85% or greater. The number of patients per arm was set at 400 for an approximate total of 1,200 patients.</p>
                <p>Two main overall comparisons of the primary end point were plannedâone between Arm V and Arm P and the other between Arm VG and Arm Pâand these were performed using a Bonferroni correction for the overall type I error probability such that the probability for each one-sided comparison would not exceed 0.0125 (0.025/2). Trial success was defined as meeting the statistical criterion for either comparison. The same comparisons performed for survival were performed for AWE using the same significance levels. AWE end point was analyzed using a logistic regression model stratified by randomization strata. The 95% CI for the odds ratio (OR) estimate was computed as the measure of effect size.</p>
                <p>Three interim analyses were planned for OS superiority and futility after 321, 481, and 641 deaths, which represented 40%, 60%, and 80% of the deaths required for final analysis (801 deaths in the three arms). In addition to the OâBrien-Fleming efficacy stopping boundaries to control the overall type I error, a significance level of 0.00001 was used for detection of futility at each interim analysis. An unblinded independent third-party vendor performed interim analyses. Results were assessed by an independent data monitoring committee. SAS (SAS/STAT Userâs Guide, Version 9.2; SAS Institute, Cary, NC) was used for all statistical analyses.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s7">
              <title>RESULTS</title>
              <sec id="s8">
                <title>Patient Characteristics and Disposition</title>
                <p>A total of 1,749 patients from 105 sites in 16 countries were screened, and 1,297 were randomly assigned to one of the three treatment arms, comprising the intention-to-treat population. Of these, 11 patients were never treated; therefore, the full analysis set/safety population consisted of 1,286 patients. The first patient was screened in November 2011 and the last patient completed the treatment phase in July 2015. After the third interim analysis, criteria for futility were met and, on the recommendation of the DMC, the trial was stopped early (September 25, 2017) and the date of last follow-up was October 02, 2017. A flowchart of patient enrollment and disposition is shown in <xref ref-type="fig" rid="f1">Figure 1</xref>. A similar proportion of treated patients in all arms (65% to 70%) completed the treatment period. Reasons for discontinuation were also similar among the study arms, with progressive disease (23.4%; 301 of 1,286 patients) being the most common, whereas adverse events accounted for 3.5% (45 of 1,286 patients) of all treatment discontinuations.</p>
                <fig id="f1" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Patient disposition. Safety was assessed using the full analysis set population (FAS). Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor; ITT, intention-to-treat population, LTFU, long-term follow-up.</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031f1"/>
                </fig>
                <p>The majority of treated patients in each arm (94% to 96%) entered the LTFU phase (<xref ref-type="fig" rid="f1">Fig 1</xref>). As follow-up was to continue until death as a result of any cause, death was the most common reason for discontinuation from LTFU. Given the DMC recommendation to stop the trial early, the second most common reason was study termination by sponsor.</p>
                <p>Patients were evenly distributed across the treatment arms by demographic and disease characteristics (<xref rid="T1" ref-type="table">Table 1</xref>). Mean age of the study population was 71 years (range, 45 to 93 years), and the primary site of metastasis in all study arms was bone, occurring in approximately 75% of patients. Approximately one third of all patients reported a history of cardiac disorders, with coronary artery disorders being the most common at approximately 20%.</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Baseline Demographics and Disease Characteristics</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031t1"/>
                </table-wrap>
              </sec>
              <sec id="s9">
                <title>Primary End Point</title>
                <p>As shown in the Kaplan-Meier curves (<xref ref-type="fig" rid="f2">Fig 2</xref>), the two active arms were not different from placebo with respect to OS. Median OS was 34.4 months in Arm V, 33.2 months in Arm VG, and 34.3 months in Arm P. The hazard ratio for comparison with placebo was 1.01 (95% CI, 0.84 to 1.20; <italic>P</italic> = .47) for Arm V and 1.02 (95% CI, 0.86 to 1.22; <italic>P</italic> = .59) for Arm VG.</p>
                <fig id="f2" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 2.</label>
                  <caption>
                    <p>Kaplan-Meier estimates for overall survival (OS). Arm P, placebo; Arm V, PROSTVAC; Arm VG, PROSTVAC + granulocyte-macrophage colony-stimulating factor; HR, hazard ratio.</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031f2"/>
                </fig>
              </sec>
              <sec id="s10">
                <title>Secondary End Point</title>
                <p>Likewise, the proportion of patients AWE at 6 months postrandomization was similar across treatment arms (Arm V; 29.4%; OR, 0.96; 95% CI, 0.71 to 1.29; Arm VG: 28.0%; OR, 0.89; 95% CI, 0.66 to 1.20; Arm P: 30.3%; <xref rid="T2" ref-type="table">Table 2</xref>). The most common event was radiographic progression, which occurred in approximately 60% of patients, followed by pain progression, which ranged from 6.5% in Arm V to 10.4% in Arm P.</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Patients at 6 Months Postrandomization</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031t2"/>
                </table-wrap>
              </sec>
              <sec id="s11">
                <title>Exploratory/Other End Points</title>
                <p>HLA-A2 statusâpositive versus negativeâdid not influence OS (<xref rid="T3" ref-type="table">Table 3</xref>). Whereas there were significant differences in OS between postvaccination cancer therapyâyes versus noâand between tumor growth rate quartiles, there were no differences between treatments within each subgroup (<xref rid="T3" ref-type="table">Table 3</xref>, Data Supplement Figures A2, A3).</p>
                <table-wrap id="T3" orientation="portrait" position="float">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Median Overall Survival by Selected Subgroups</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031t3"/>
                </table-wrap>
                <p>Tumor response results were similar across treatments (<xref rid="T4" ref-type="table">Table 4</xref>, Data Supplement Figure A1). At week 25/end of treatment, only one patient achieved a complete response and this was observed in a placebo-treated patient. A best response of partial response was observed in less than 1% of patients in each study arm.</p>
                <table-wrap id="T4" orientation="portrait" position="float">
                  <label>TABLE 4.</label>
                  <caption>
                    <p>Best Overall Response by RECIST and Minimum Percentage Change in PSA Through Week 25/End-of-Treatment</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031t4"/>
                </table-wrap>
              </sec>
              <sec id="s12">
                <title>Safety</title>
                <p>Nearly all treated patientsâapproximately 91%âexperienced at least one treatment-emergent adverse event (TEAE). As expected, the most common events in all three treatment arms were injection site reactions, which occurred in 62% to 72% of patients. The most common noninjection site event for all treatment arms was fatigue, which occurred in 21% to 24% of patients. Whereas at least one grade 3 or greater TEAE was reported in 21% to 23% of patients, the majority (more than 75%) of all TEAEs were mild in severity (grade 1). Adverse events that led to treatment discontinuation occurred in 4.9% (21 of 429 patients), 6.5% (28 of 429 patients), and 5.8% (25 of 428 patients) of patients in Arm V, Arm VG, and Arm P, respectively. In only a minority of patients were the events considered treatment related (Arm V: 0.9% [four of 429 patients]; Arm VG: 3.0% [13 of 429 patients]; Arm P: 1.6% [seven of 428 patients]). The most common TEAEs that led to treatment discontinuation in the study arms were bone pain (n = 6; two patients in each treatment arm) and spinal cord compression (n = 6; one patient in each PROSTVAC arm and four patients in the placebo arm). A total of nine patients (Arm V, n = 3; Arm VG, n = 4; Arm P, n = 2) experienced 10 serious adverse events that were considered by study investigators to be treatment related, but no single event occurred in more than one patient each per study arm. The most common treatment-related TEAEs by toxicity grade are shown in <xref rid="T5" ref-type="table">Table 5</xref>. Overall, treatment-related adverse events were more commonly observed in Arm VG (79.3%) compared with Arm V (72.7%) or placebo (70.6%), and this was especially noticeable with pyrexia (19.3%, 6.5%, and 11.0%, respectively) and injection site reactions. Cardiac disorders occurred in less than 5% of all treated patients, with no differences across treatment arms. Arrhythmias were the most commonly reported cardiac-related TEAEs, occurring in 1.4% (Arm VG) to 3.5% (placebo) of all patients. There were no reports of myocarditis or pericarditis.</p>
                <table-wrap id="T5" orientation="portrait" position="float">
                  <label>TABLE 5.</label>
                  <caption>
                    <p>Adverse Events Reported as Treatment-Related in 10% of Patients or Greater</p>
                  </caption>
                  <graphic xlink:href="JCO.18.02031t5"/>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s13">
              <title>DISCUSSION</title>
              <p>In this phase III study, PROSTVAC did not meet the primary OS end point compared with control in patients with asymptomatic or minimally symptomatic mCRPC. These results did not support the positive signal from the randomized phase II study.<sup><xref rid="B14" ref-type="bibr">14</xref></sup></p>
              <p>A few possibilities may account for these findings: the phase II finding generated a false-positive signal as a result of being underpowered for an OS comparison, the relatively small sample size (82 PROSTVAC-treated <italic>v</italic> 40 placebo-treated patients), and/or potential observer bias (long-term OS data were collected after database lock and study unblinding).<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref></sup> Moreover, an imbalance in prognostic factors, both known and unknown, may have negatively affected the observed median OS in the phase II control arm (16.6 months). This was lower than expected compared with the Halabi prognostic nomogram-predicted OS (PSA, lactate dehydrogenase, alkaline phosphatase, and hemoglobin; 20.4 months).<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B20" ref-type="bibr">20</xref></sup> Survival in the control arm relative to expected outcomes may be the origin of the flawed comparison, which is supported by the OS in the control arm of the sipuleucel-T pivotal trial (21.7 months).<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Finally, docetaxel was the only life-prolonging treatment available during our phase II study. From the time the phase III protocol was finalized (2010) until the last patient was randomly assigned (January 2015), multiple treatments became availableâcabazitaxel,<sup><xref rid="B9" ref-type="bibr">9</xref></sup> sipuleucel-T,<sup><xref rid="B10" ref-type="bibr">10</xref></sup> abiraterone acetate<sup><xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref></sup> enzalutamide,<sup><xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref></sup> and radium-223<sup><xref rid="B11" ref-type="bibr">11</xref></sup>âand we observed an approximate 3-year median OS in the placebo group. It should be noted that in similar predocetaxel patient populations, OS benefit in clearly clinically active agentsâabiraterone and enzalutamideâwas less robust than in postchemotherapy, likely because of subsequent therapies.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B6" ref-type="bibr">6</xref></sup> It is possible that these life-prolonging therapies negatively affected the likelihood of this trial achieving positive results. Despite this statistical possibility, the lack of any signal of efficacy indicates that PROSTVAC, as a single agent in this setting, seems to be ineffective at a level that would justify the treatment of unselected patients. Preclinical evidence suggested that PROSTVAC generated fully functional T cells that were capable of trafficking to and infiltrating into murine models of prostate cancer.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> Accumulated immune data from multiple National Cancer Institute clinical trials also suggested that antitumor immune responses could be identified in the peripheral blood.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> The observed lack of clinical signal suggests that either the immune responses generated in this study were not sufficient or there were other negative regulatory influences in the tumor microenvironment that prevented clinically relevant immune-mediated killing.</p>
              <p>GM-CSF has been adopted by cancer vaccine developers on the basis of its properties of differentiation, migration, and activation of dendritic cells, including an enhancement of antigen cross-presentation<sup><xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref></sup>; however, biologic effects of GM-CSF also stimulate other myeloid cells, including myeloid-derived suppressor cells, which inhibit the functionality of T cells.<sup><xref rid="B25" ref-type="bibr">25</xref>-<xref rid="B27" ref-type="bibr">27</xref></sup> We observed an increase in adverse events in the treatment arm that contained GM-CSF, and as a result of the overall lack of efficacy of PROSTVAC versus placebo, our data do not support any definitive recommendation about GM-CSF, positive or negative. Therefore, use of GM-CSF as a vaccine adjuvant must still be considered investigational.</p>
              <p>A correlation between growth rate constant and survival has been reported in a retrospective analysis of five phase II clinical trials.<sup><xref rid="B28" ref-type="bibr">28</xref></sup> Our data are in agreement, showing a strong correlation between slower growth rate constant and longer survival regardless of treatment group. Our data, however, cannot confirm the hypothesis that patients with more indolent mCRPC derive greater benefit from vaccine therapy than do those with poorer prognostic factors,<sup><xref rid="B29" ref-type="bibr">29</xref></sup> considering the absence of an OS benefit in the entire study population. Nonetheless, we have demonstrated that tumor growth rate, as measured by the model used in this study, is a reasonable predictor of the risk of death on a population level. This tool could be used in clinical trials to stratify or select patients who are at high or low risk for death, as appropriate for the primary study end point.</p>
              <p>PROSTVAC was found to be safe and well tolerated, with no unexpected TEAEs, which confirmed the result of earlier studies.<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B30" ref-type="bibr">30</xref></sup> Overall, TEAEs were similar to placebo and most commonly related to injection site reactions. An increased risk for myocarditis or pericarditis has been observed with replicating vaccinia virus strains used as preventive vaccines for smallpox (variola).<sup><xref rid="B31" ref-type="bibr">31</xref>-<xref rid="B33" ref-type="bibr">33</xref></sup> As PROSTVAC uses a replicating vaccinia strain as the vector, cardiac adverse events are a safety issue of special interest. No signal of cardiotoxicity was observed in our study, even with the population being in the high-risk category for cardiovascular eventsâthat is, male, older than age 65 years (approximately 75% of our population were older than age 65 years).<sup><xref rid="B34" ref-type="bibr">34</xref></sup></p>
              <p>Therapeutic cancer vaccines remain a valid immunotherapy option for prostate cancer, as supported by the survival benefit of sipuleucel-T.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> The choice of proper target antigens and adjuvant components that can overcome immune resistance within the tumor microenvironment are of critical importance. Along with the confounding factors that surround additional treatment options that became available during our study, it is not known, for instance, if the selection of prostatic acid phosphatase in sipuleucel-T versus PSA in PROSTVAC played a role in efficacy evaluation.</p>
              <p>In conclusion, we observed that vaccines induce T cells that are capable of infiltrating tumors, but that this immune response does not translate into clinical benefit poses a major challenge to the immunotherapy community. Historical data have shown that PROSTVAC is capable of generating specific T-cell responses against PSA as well as cascade antigens,<sup><xref rid="B22" ref-type="bibr">22</xref></sup> indicating that the poxvirus platform has the potential to induce clinical benefit in the right contextâthat is, with different antigen targets, in other disease settings, and in combination with checkpoint inhibition. This possibility is being evaluated in ongoing clinical trials.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn id="fn5" fn-type="presented-at" specific-use="presented-at">
                <p>Presented in part at the American Society of Clinical Oncology 2018 Annual Meeting, Chicago, IL, June 1-5, 2018.</p>
              </fn>
              <fn id="fn4" fn-type="supported-by" specific-use="supported-by">
                <p>Supported by Bavarian Nordic, the National Institute for Health Research Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust, and the Institute of Cancer Research. Funded in part by National Cancer Institute Cancer Center Support Grant No. P30-CA008748 and the Center for Cancer Research, National Cancer Institute.</p>
              </fn>
              <fn id="fn1" fn-type="other" specific-use="other">
                <p>Processed as a Rapid Communication manuscript.</p>
              </fn>
              <fn id="fn2" fn-type="other" specific-use="other">
                <p>The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.</p>
              </fn>
              <fn id="fn3" fn-type="trial" specific-use="trial">
                <p>Clinical trial information: NCT01322490.</p>
              </fn>
            </fn-group>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>The authors thank all the patients who participated in the trial and their families. The authors also thank members of the study team (Bavarian Nordic) and Cesar Pico-Navarro (Bavarian Nordic) for scientific contribution. Medical writing and editorial support was provided by Lorraine R. Baer, PharmD, of Baer PharMed Consulting and funded by Bavarian-Nordic.</p>
            </ack>
            <sec id="s15">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> James L. Gulley, Neal D. Shore, Winald R. Gerritsen, Niels C. Langkilde, Philip W. Kantoff</p>
              <p><bold>Financial support:</bold> Christopher R. Heery</p>
              <p><bold>Administrative support:</bold> Neal D. Shore, Christopher R. Heery, Andrey Novikov</p>
              <p><bold>Provision of study materials or patients:</bold> James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, David W. Pook, Joan Carles, Fred Saad, Winald R. Gerritsen, Frank Priou, Niels C. Langkilde, Andrey Novikov</p>
              <p><bold>Collection and assembly of data:</bold> James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris C. Parker, David W. Pook, Per Rathenborg, Thomas W. Flaig, Fred Saad, Liddy Chen, Christopher R. Heery, Frank Priou</p>
              <p><bold>Data analysis and interpretation:</bold> James L. Gulley, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Niels C. Langkilde, Andrey Novikov, Philip W. Kantoff</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec id="s16">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec id="s17">
                <title>Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://ascopubs.org/jco/site/ifc">ascopubs.org/jco/site/ifc</ext-link>.</p>
              </sec>
              <sec id="s18">
                <title>James L. Gulley</title>
                <p><bold>Research Funding:</bold> EMD Serono (Inst), Bavarian Nordic (Inst), Astellas Medivation (Inst), Pfizer (Inst), NantBioScience (Inst), Bristol-Myers Squibb (Inst), Merck (Inst)</p>
              </sec>
              <sec id="s19">
                <title>Michael Borre</title>
                <p><bold>Honoraria:</bold> Janssen-Cilag, Astellas Pharma, Amgen, Sanofi</p>
              </sec>
              <sec id="s20">
                <title>Nicholas J. Vogelzang</title>
                <p><bold>Employment:</bold> US Oncology</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Caris Life Sciences</p>
                <p><bold>Honoraria:</bold> UpToDate, Pfizer, Novartis</p>
                <p><bold>Consulting or Advisory Role:</bold> Pfizer, Bayer, Genentech, Heron, AstraZeneca, Caris Life Sciences, Fujifilm, Tolero Pharmaceuticals, Merck, Astellas Pharma, Boehringer Ingelheim</p>
                <p><bold>Speakers' Bureau:</bold> Bayer, Sanofi, Genentech, Bristol-Myers Squibb, Exelixis, AstraZeneca, MedImmune</p>
                <p><bold>Research Funding:</bold> US Oncology (Inst), Endocyte (Inst), Merck (Inst), Suzhou Kintor Pharmaceuticals (Inst)</p>
                <p><bold>Expert Testimony:</bold> Novartis</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Genentech, US Oncology, Pfizer, Bayer, Onyx Pharmaceuticals, Exelixis, AstraZeneca, MedImmune, Sanofi</p>
              </sec>
              <sec id="s21">
                <title>Siobhan Ng</title>
                <p><bold>Honoraria:</bold> Astellas Pharma, Amgen, MSD Oncology, Bayer, Johnson &amp; Johnson, Ipsen, Pfizer</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Astellas Pharma, Amgen</p>
              </sec>
              <sec id="s22">
                <title>Neeraj Agarwal</title>
                <p><bold>Consulting or Advisory Role:</bold> Pfizer, Exelixis, Medivation, Astellas, Eisai, Merck, Novartis, EMD Serono, Clovis Oncology, Genentech, Bristol-Myers Squibb, AstraZeneca, Nektar, Eli Lilly, Bayer, Foundation One, Argos Therapeutics</p>
                <p><bold>Research Funding:</bold> Bayer (Inst), Bristol-Myers Squibb (Inst), GlaxoSmithKline (Inst), Medivation (Inst), Takeda (Inst), Novartis (Inst), Pfizer (Inst), BN ImmunoTherapeutics (Inst), Exelixis (Inst), TRACON Pharma (Inst), Rexahn Pharmaceuticals (Inst), Amgen (Inst), AstraZeneca (Inst), Active Biotech (Inst), Bavarian Nordic (Inst), Calithera Biosciences (Inst), Celldex (Inst), Eisai (Inst), Genentech (Inst), Immunomedics (Inst), Janssen Pharmaceuticals (Inst), Merck (Inst), Newlink Genetics (Inst), Prometheus (Inst), Sanofi (Inst)</p>
              </sec>
              <sec id="s23">
                <title>Chris C. Parker</title>
                <p><bold>Honoraria:</bold> Bayer, Janssen Pharmaceuticals, Advanced Accelerator Applications</p>
                <p><bold>Consulting or Advisory Role:</bold> Bayer Schering Pharma, Janssen Pharmaceuticals</p>
                <p><bold>Research Funding:</bold> Bayer Schering Pharma (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Bayer Schering Pharma, Janssen Pharmaceuticals</p>
              </sec>
              <sec id="s24">
                <title>David W. Pook</title>
                <p><bold>Honoraria:</bold> Astellas Pharma, Ipsen, Novartis</p>
                <p><bold>Consulting or Advisory Role:</bold> Bristol-Myers Squibb, Pfizer, Merck Sharp &amp; Dohme (Inst)</p>
                <p><bold>Research Funding:</bold> Medivation (Inst), Bristol-Myers Squibb (Inst), Roche (Inst), Exelixis (Inst), Merck Sharp &amp; Dohme (Inst), Pfizer (Inst), Astellas Pharma (Inst), Bayer (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Bristol-Myers Squibb, Astellas Pharma, Pfizer</p>
              </sec>
              <sec id="s25">
                <title>Thomas W. Flaig</title>
                <p><bold>Leadership:</bold> Aurora Oncology</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Aurora Oncology</p>
                <p><bold>Honoraria:</bold> BN ImmunoTherapeutics</p>
                <p><bold>Consulting or Advisory Role:</bold> GTx</p>
                <p><bold>Research Funding:</bold> Novartis, Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol-Myers Squibb, Genentech, Exelixis, Aragon Pharmaceuticals, Sotio, Tokai Pharmaceuticals, AstraZeneca, MedImmune, Eli Lilly, Astellas Pharma, Agensys, Seattle Genetics, La Roche-Posay</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> The University of Colorado has filed two patents related in which I am an inventor related to early-stage bladder cancer treatment and detection; neither is commercialized or licensed at this time</p>
              </sec>
              <sec id="s26">
                <title>Joan Carles</title>
                <p><bold>Consulting or Advisory Role:</bold> Bayer, Johnson &amp; Johnson, Bristol-Myers Squibb, Astellas Pharma, Pfizer, Sanofi, MSD Oncology, Roche</p>
                <p><bold>Speakers' Bureau:</bold> Bayer, Johnson &amp; Johnson, Asofarma, Astellas Pharma</p>
              </sec>
              <sec id="s27">
                <title>Fred Saad</title>
                <p><bold>Honoraria:</bold> Astellas Pharma, Janssen Oncology, Sanofi, Bayer, AstraZeneca</p>
                <p><bold>Consulting or Advisory Role:</bold> Astellas Pharma, Janssen Oncology, Sanofi, AstraZeneca, MedImmune, Bayer</p>
                <p><bold>Research Funding:</bold> Astellas Pharma (Inst), Bayer (Inst), Janssen Oncology (Inst), Sanofi (Inst), AstraZeneca (Inst)</p>
              </sec>
              <sec id="s28">
                <title>Neal D. Shore</title>
                <p><bold>Consulting or Advisory Role:</bold> Bayer, Janssen Scientific Affairs, Dendreon, Tolmar, Ferring, Medivation, Astellas Pharma, Amgen, Pfizer, AstraZeneca, Genentech, Myovant Sciences</p>
                <p><bold>Speakers' Bureau:</bold> Janssen Pharmaceuticals, Bayer, Dendreon</p>
              </sec>
              <sec id="s29">
                <title>Liddy Chen</title>
                <p><bold>Employment:</bold> Bavarian Nordic</p>
              </sec>
              <sec id="s30">
                <title>Christopher R. Heery</title>
                <p><bold>Employment:</bold> Bavarian Nordic</p>
                <p><bold>Leadership:</bold> Bavarian Nordic</p>
                <p><bold>Stock and Other Ownership Interests:</bold> Bavarian Nordic</p>
                <p><bold>Honoraria:</bold> MPM Capital</p>
                <p><bold>Consulting or Advisory Role:</bold> MPM Capital</p>
              </sec>
              <sec id="s31">
                <title>Winald R. Gerritsen</title>
                <p><bold>Consulting or Advisory Role:</bold> Sanofi (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Amgen (Inst), Astellas Pharma (Inst)</p>
                <p><bold>Speakers' Bureau:</bold> Merck Sharp &amp; Dohme, Bayer</p>
                <p><bold>Research Funding:</bold> Astellas Pharma (Inst), Janssen-Cilag (Inst), Bayer (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Merck Sharp &amp; Dohme</p>
              </sec>
              <sec id="s32">
                <title>Philip W. Kantoff</title>
                <p><bold>Stock and Other Ownership Interests:</bold> Placon, Druggablity Technologies, Tarveda Therapeutics, Context Therapeutics, Seer</p>
                <p><bold>Consulting or Advisory Role:</bold> Bavarian Nordic, Janssen Pharmaceuticals, BIND Biosciences, Metamark Genetics, Merck, OncoCellMDX, Sanofi, Genentech, Tarveda Therapeutics, Druggablity Technologies, Progenity, Thermo Fisher Scientific, Context Therapeutics, GE Healthcare, New England Research Institutes, Seer</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Method for predicting the risk of prostate cancer morbidity and mortality, predicting and treating prostate cancer, methods for predicting likelihood of responding to treatment, chromosome copy number gain as a biomarker of urothelial carcinoma lethality, drug combinations to treat cancer, somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma (patent), Up-to-Date royalties, Wolters Kluwer royalties, methods and kits for determining sensitivity to cancer treatment, composition and methods for screening and diagnosis of prostate cancer</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Sanofi, Druggablity Technologies</p>
                <p>No other potential conflicts of interest were reported.</p>
              </sec>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Basch</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Loblaw</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Oliver</surname>
                      <given-names>TK</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline</article-title>
                  <source>J Clin Oncol</source>
                  <volume>32</volume>
                  <fpage>3436</fpage>
                  <lpage>3448</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">25199761</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Virgo</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Basch</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Loblaw</surname>
                      <given-names>DA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Second-line hormonal therapy for men with chemotherapy-naÃ¯ve, castration-resistant prostate cancer: American Society of Clinical Oncology provisional clinical opinion</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <fpage>1952</fpage>
                  <lpage>1964</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28441112</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Molina</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study</article-title>
                  <source>Lancet Oncol</source>
                  <volume>13</volume>
                  <fpage>983</fpage>
                  <lpage>992</lpage>
                  <year>2012</year>
                  <comment>Errata: Lancet Oncol 13:e464, 2012; Lancet Oncol 15:e365, 2014</comment>
                  <pub-id pub-id-type="pmid">22995653</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ryan</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study</article-title>
                  <source>Lancet Oncol</source>
                  <volume>16</volume>
                  <fpage>152</fpage>
                  <lpage>160</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25601341</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Increased survival with enzalutamide in prostate cancer after chemotherapy</article-title>
                  <source>N Engl J Med</source>
                  <volume>367</volume>
                  <fpage>1187</fpage>
                  <lpage>1197</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">22894553</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beer</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Armstrong</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Rathkopf</surname>
                      <given-names>DE</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Enzalutamide in metastatic prostate cancer before chemotherapy</article-title>
                  <source>N Engl J Med</source>
                  <volume>371</volume>
                  <fpage>424</fpage>
                  <lpage>433</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">24881730</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petrylak</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Tangen</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Hussain</surname>
                      <given-names>MH</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>351</volume>
                  <fpage>1513</fpage>
                  <lpage>1520</lpage>
                  <year>2004</year>
                  <pub-id pub-id-type="pmid">15470214</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Berthold</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Pond</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Soban</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study</article-title>
                  <source>J Clin Oncol</source>
                  <volume>26</volume>
                  <fpage>242</fpage>
                  <lpage>245</lpage>
                  <year>2008</year>
                  <pub-id pub-id-type="pmid">18182665</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Oudard</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ozguroglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial</article-title>
                  <source>Lancet</source>
                  <volume>376</volume>
                  <fpage>1147</fpage>
                  <lpage>1154</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20888992</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Shore</surname>
                      <given-names>ND</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>363</volume>
                  <fpage>411</fpage>
                  <lpage>422</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20818862</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parker</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Nilsson</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Heinrich</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Alpha emitter radium-223 and survival in metastatic prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>369</volume>
                  <fpage>213</fpage>
                  <lpage>223</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23863050</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Madan</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Arlen</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Mohebtash</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>PROSTVAC-VF: A vector-based vaccine targeting PSA in prostate cancer</article-title>
                  <source>Expert Opin Investig Drugs</source>
                  <volume>18</volume>
                  <fpage>1001</fpage>
                  <lpage>1011</lpage>
                  <year>2009</year>
                </mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arlen</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Skarupa</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Pazdur</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Clinical safety of a viral vector based prostate cancer vaccine strategy</article-title>
                  <source>J Urol</source>
                  <volume>178</volume>
                  <fpage>1515</fpage>
                  <lpage>1520</lpage>
                  <year>2007</year>
                  <pub-id pub-id-type="pmid">17707059</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Schuetz</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Blumenstein</surname>
                      <given-names>BA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>28</volume>
                  <fpage>1099</fpage>
                  <lpage>1105</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20100959</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Grosenbach</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Barrientos</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Schlom</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects</article-title>
                  <source>Cancer Res</source>
                  <volume>61</volume>
                  <fpage>4497</fpage>
                  <lpage>4505</lpage>
                  <year>2001</year>
                  <pub-id pub-id-type="pmid">11389081</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Gulley</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Pico-Navarro</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <fpage>124</fpage>
                  <lpage>125</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">27646950</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kass</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Panicali</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Mazzara</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant</article-title>
                  <source>Cancer Res</source>
                  <volume>61</volume>
                  <fpage>206</fpage>
                  <lpage>214</lpage>
                  <year>2001</year>
                  <pub-id pub-id-type="pmid">11196163</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Faries</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Hsueh</surname>
                      <given-names>EC</given-names>
                    </name>
                    <name>
                      <surname>Ye</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>15</volume>
                  <fpage>7029</fpage>
                  <lpage>7035</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19903777</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Slingluff</surname>
                      <given-names>CL</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Petroni</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Olson</surname>
                      <given-names>WC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>15</volume>
                  <fpage>7036</fpage>
                  <lpage>7044</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19903780</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Halabi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>21</volume>
                  <fpage>1232</fpage>
                  <lpage>1237</lpage>
                  <year>2003</year>
                  <pub-id pub-id-type="pmid">12663709</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mandl</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Rountree</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Dela Cruz</surname>
                      <given-names>TB</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy</article-title>
                  <source>J Immunother Cancer</source>
                  <volume>2</volume>
                  <fpage>34</fpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">25328681</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gulley</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Madan</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Tsang</surname>
                      <given-names>KY</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer</article-title>
                  <source>Cancer Immunol Res</source>
                  <volume>2</volume>
                  <fpage>133</fpage>
                  <lpage>141</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">24778277</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Disis</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Bernhard</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Shiota</surname>
                      <given-names>FM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines</article-title>
                  <source>Blood</source>
                  <volume>88</volume>
                  <fpage>202</fpage>
                  <lpage>210</lpage>
                  <year>1996</year>
                  <pub-id pub-id-type="pmid">8704175</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chang</surname>
                      <given-names>DZ</given-names>
                    </name>
                    <name>
                      <surname>Lomazow</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Joy Somberg</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Granulocyte-macrophage colony stimulating factor: An adjuvant for cancer vaccines</article-title>
                  <source>Hematology</source>
                  <volume>9</volume>
                  <fpage>207</fpage>
                  <lpage>215</lpage>
                  <year>2004</year>
                  <pub-id pub-id-type="pmid">15204102</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Serafini</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Carbley</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Noonan</surname>
                      <given-names>KA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells</article-title>
                  <source>Cancer Res</source>
                  <volume>64</volume>
                  <fpage>6337</fpage>
                  <lpage>6343</lpage>
                  <year>2004</year>
                  <pub-id pub-id-type="pmid">15342423</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Filipazzi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Valenti</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Huber</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine</article-title>
                  <source>J Clin Oncol</source>
                  <volume>25</volume>
                  <fpage>2546</fpage>
                  <lpage>2553</lpage>
                  <year>2007</year>
                  <pub-id pub-id-type="pmid">17577033</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ribechini</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Hutchinson</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Hergovits</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Novel GM-CSF signals via IFN-Î³R/IRF-1 and AKT/mTOR license monocytes for suppressor function</article-title>
                  <source>Blood Adv</source>
                  <volume>1</volume>
                  <fpage>947</fpage>
                  <lpage>960</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">29296736</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stein</surname>
                      <given-names>WD</given-names>
                    </name>
                    <name>
                      <surname>Gulley</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Schlom</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>17</volume>
                  <fpage>907</fpage>
                  <lpage>917</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21106727</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gulley</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Arlen</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Madan</surname>
                      <given-names>RA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer</article-title>
                  <source>Cancer Immunol Immunother</source>
                  <volume>59</volume>
                  <fpage>663</fpage>
                  <lpage>674</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">19890632</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>DiPaola</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Plante</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kaufman</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer</article-title>
                  <source>J Transl Med</source>
                  <volume>4</volume>
                  <fpage>1</fpage>
                  <year>2006</year>
                  <pub-id pub-id-type="pmid">16390546</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Arness</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Eckart</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Love</surname>
                      <given-names>SS</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Myopericarditis following smallpox vaccination</article-title>
                  <source>Am J Epidemiol</source>
                  <volume>160</volume>
                  <fpage>642</fpage>
                  <lpage>651</lpage>
                  <year>2004</year>
                  <pub-id pub-id-type="pmid">15383408</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morgan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Roper</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Sperling</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003</article-title>
                  <source>Clin Infect Dis</source>
                  <volume>46</volume>
                  <fpage>S242</fpage>
                  <lpage>S250</lpage>
                  <year>2008</year>
                  <issue>suppl 3</issue>
                  <pub-id pub-id-type="pmid">18284365</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petersen</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Damon</surname>
                      <given-names>IK</given-names>
                    </name>
                    <name>
                      <surname>Pertowski</surname>
                      <given-names>CA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Clinical guidance for smallpox vaccine use in a postevent vaccination program</article-title>
                  <source>MMWR Recomm Rep</source>
                  <volume>64</volume>
                  <fpage>1</fpage>
                  <lpage>26</lpage>
                  <year>2015</year>
                </mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Curry</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Krist</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Owens</surname>
                      <given-names>DK</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement</article-title>
                  <source>JAMA</source>
                  <volume>320</volume>
                  <fpage>272</fpage>
                  <lpage>280</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29998297</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
